



Alkermes' Corporate Presentation to be Webcast at the NASDAQ Investor Program

November 29, 2007

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 29, 2007--Alkermes, Inc. (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live by NASDAQ International on Thursday, December 6, 2007 at 9 a.m. GMT (4 a.m. EST). The presentation will be webcast from Renaissance Chancery Court Hotel in London and may be accessed under the investor relations tab at www.alkermes.com. The presentation will be archived for 14 days.

Alkermes, Inc. is a biotechnology company that uses proprietary technologies and know-how to create innovative medicines designed to yield better therapeutic outcomes for patients with serious disease. Alkermes manufactures RISPERDAL(R) CONSTA(R), marketed by Janssen-Cilag (Janssen, L.P.), a wholly owned division of Johnson & Johnson, and developed and manufactures VIVITROL(R), marketed in the U.S. primarily by Cephalon, Inc. The company's pipeline includes extended-release injectable, pulmonary and oral products for the treatment of prevalent, chronic diseases, such as central nervous system disorders, addiction and diabetes. Alkermes is headquartered in Cambridge, Massachusetts, with research and manufacturing facilities in Massachusetts and Ohio.

CONTACT: Alkermes, Inc.
Eva Stroynowski, 617-583-6823
Associate, Corporate Communications

SOURCE: Alkermes, Inc.